OBJECTIVES To measure adverse pathologic outcomes following radical prostatectomy (RP) for men with low-risk prostate cancer in the United States based on time from diagnosis to surgery. METHODS We extracted data from the National Cancer Database in 2010 and 2011 on 17,943 low-risk patients (Gleason score = 3+3, prostate-specific antigen < 10 ng/ml, and cT1-T2) who underwent RP. We identified...

Social media recently became convenient platforms for different groups with common concerns to share their experiences, including Adverse Drug Reactions (ADRs). In this paper, we propose a two stage intelligent algorithm which call “Simi_to_Prob”, that utilizes social forums; ranking ADRs, and evaluating the ADRs prevalence considering age gender as its first stage. second stage, are predicted ...

Proton pump inhibitors effectively treat gastroesophageal reflux disease, erosive esophagitis, duodenal ulcers, and pathologic hypersecretory conditions. Proton pump inhibitors cause few adverse effects with short-term use; however, long-term use has been scrutinized for appropriateness, drug-drug interactions, and the potential for adverse effects (e.g., hip fractures, cardiac events, iron def...

Hypertrophic pulmonary osteoarthropathy (HPOA), mainly manifested clubbing, is rare in patients with esophageal sarcomatoid carcinoma. We herein describe a 48-year-old Chinese man whose advanced carcinoma was diagnosed while examining his symptoms of HPOA. The patient had no opportunity surgery after surgical evaluation. Chemoradiation, including 5 cycles chemotherapy (Paclitaxel liposome 60 mg...

BACKGROUND Head and neck hemangiopericytoma (HNHPC) is rare. Treatment outcome and specific prognostic factors were unexplored. METHODS A case meta-analysis, in which treatment and outcome data were available, was performed. RESULTS A total of 116 primary HNHPC cases were analyzed. Poor pathologic differentiation was associated with increased risk of tumor recurrence (odds ratio [OR] = 2.37...

To assess the impact of lymphovascular invasion (LVI) on the risk of biochemical recurrence (BCR) in pT3 N0 prostate cancer, clinical data were extracted from 1,622 patients with pT3 N0 prostate cancer from the K-CaP database. Patients with neoadjuvant androgen deprivation therapy (n = 325) or insufficient pathologic or follow-up data (n = 87) were excluded. The primary endpoint was the oncolog...